Biotech firm's COVID-19 detection kit greenlighted for launch

It can now be used directly by laboratories or hospitals to test patients for clinical diagnosis.

Singapore-based biotech firm Veredus Laboratories has obtained the provisional authorisation from Singapore Health Sciences Authority (HSA) for its COVID-19 detection kit.

Dubbed as VereCoV Detection Kit, the device can now be used directly by laboratories or hospitals to test patients for clinical diagnosis. The kit was launched for research use only (RUO) test earlier this year.

It integrates an ultra-fast miniaturised PCR reactor for the amplification of nucleic acids and a customised microarray to qualitatively detect COVID-19 with the additional capability of detecting a subset of Severe Acute Respiratory Syndrome (SARS-CoV) within the same test.

Veredus also mentioned that this was made in collaboration with the Home Team Science and Technology Agency’s (HTX) Chemical, Biological, Radiology, Nuclear and Explosives (CBRNE) Centre of Expertise.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia